A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
- Conditions
- DyslipidemiaHypercholesterolemiaHigh Cholesterol
- Interventions
- Drug: PlaceboDrug: Obicetrapib
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- NewAmsterdam Pharma
- Target Recruit Count
- 102
- Registration Number
- NCT05421078
- Locations
- π―π΅
Nippon Kokan Fukuyama Hospital, Fukuyama, Japan
π―π΅Kishiwada Tokushu-Kai Hospital, Osaka, Japan
π―π΅Nakamura Cardiology and Cardiovascular Surgery Clinic, Itoshima, Japan
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
- Conditions
- HypercholesterolemiaHigh CholesterolDyslipidemias
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- NewAmsterdam Pharma
- Target Recruit Count
- 119
- Registration Number
- NCT05266586
- Locations
- πΊπΈ
Valley Clinical Trials, Inc., Northridge, California, United States
πΊπΈOcala Cardiovascular Research, Ocala, Florida, United States
πΊπΈProgressive Medical Research, Port Orange, Florida, United States
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: PlaceboDrug: Obicetrapib
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- NewAmsterdam Pharma
- Target Recruit Count
- 9541
- Registration Number
- NCT05202509
- Locations
- πΊπΈ
Northwest Heart Clinical research, Arlington Heights, Illinois, United States
πΊπΈEclipse Clinical Research, Tucson, Arizona, United States
πΊπΈNEA Baptist clinic, Jonesboro, Arkansas, United States
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- NewAmsterdam Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT05161715
- Locations
- π³π±
Brain Research Center Amsterdam, Amsterdam, Netherlands
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
- Conditions
- DyslipidemiasHigh CholesterolHypercholesterolemiaFamilial HypercholesterolemiaAtherosclerotic Cardiovascular Disease
- Interventions
- Drug: PlaceboDrug: Obicetrapib
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- NewAmsterdam Pharma
- Target Recruit Count
- 2532
- Registration Number
- NCT05142722
- Locations
- πΊπΈ
New Generation of Medical Research, Hialeah, Florida, United States
πΊπΈResearch Integrity, LLC, Owensboro, Kentucky, United States
πΊπΈThyroid, Endocrinology & Diabetes, PA, Dallas, Texas, United States
Randomized Study of Obicetrapib in Combination With Ezetimibe
- Conditions
- DyslipidemiasHigh CholesterolHypercholesterolemia
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- NewAmsterdam Pharma
- Target Recruit Count
- 112
- Registration Number
- NCT04770389
- Locations
- πΊπΈ
Clinical Trials Research, Lincoln, California, United States
π³π±Huisartsen Praktijk A.M.N. Zijtregto, Rotterdam, Netherlands
π³π±Huisartsen Praktijk van Soerland, Rotterdam, Netherlands
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
- Conditions
- DyslipidemiasHigh CholesterolHypercholesterolemia
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- NewAmsterdam Pharma
- Target Recruit Count
- 120
- Registration Number
- NCT04753606
- Locations
- πΊπΈ
National Research Institute - Wilshire, Los Angeles, California, United States
πΊπΈMidwest Institute for Clinical Research, Indianapolis, Indiana, United States
πΊπΈIACT Health, Columbus, Georgia, United States